Benzinga | Nov 4, 2021 07:37AM EDT

Barclays Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $148

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and lowers the price target from $160 to $148.